FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Go back to FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.53 +0.77 (0.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $125.17 | P/E | 68.80 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 4,380,650 | |||||
